跳至主要内容
临床试验/NCT00559975
NCT00559975已完成1 期

A Phase 1, Randomized, Controlled, Observer-Blinded, Dose Escalation Study of the Safety, Tolerability and Immunogenicity of a Single Dose of Adjuvanted Influenza Vaccine Combined With CpG7909 in Healthy Adults

Novartis2 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2007年10月1日最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
发起方
Novartis
入组人数
60
试验地点
2
主要终点
Measures of humoral immunogenicity for each antigen

研究概览

简要总结

To evaluate the safety and tolerability of the an adjuvanted influenza vaccine combined with CpG7909 at three different doses of CpG 7909 as a single intramuscular (IM) administration in healthy adults. Safety will be assessed by observation of symptoms, physical examination findings and laboratory safety testing.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 40 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Healthy subjects aged 18 to ≤40 years

排除标准

  • Any serious disease, hypersensitivity to egg or vaccine components, neurological symptoms or positive antibody test against dsDNA, RF, ANA or thyroid.
  • Abnormal TSH from blood samples collected during the screening visit;

结局指标

主要结局

Measures of humoral immunogenicity for each antigen

时间窗: 22 days

次要结局

  • Measures of vaccine-induced B and T cell immune responses(72 hours)
  • Measure of alterated biomarkers and measure of safety(72 hours)

研究者

发起方
Novartis
申办方类型
Industry

研究点 (2)

Loading locations...

相似试验

Safety, Tolerability, Immunogenicity And CPG Dosage... | 临床试验